Analytical Data
-
Gene name
HLA-A*11:01&B2M&KRAS G12D(VVVGADGVGK) Tetramer
- Application
-
Alternative Names
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAV53343.1 (G25-T305)&P61769
-
Expression Region
AAV53343.1 (G25-T305)&P61769 (I21-M119)&VVVGADGVGK
-
Molecular Weight
260-265 kDa under Non reducing (N)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*11:01/B2M/KRAS G12D (VVVGADGVGK) tetramer recombinant protein is pivotal in understanding immune responses to cancer, particularly in relation to KRAS mutations, which are prevalent in various malignancies such as pancreatic, colorectal, and lung cancers. KRAS G12D is a frequently occurring oncogenic mutation that not only drives tumorigenesis but also poses challenges for targeted therapies. The HLA-A*11:01 allele, a common variant in certain populations, presents peptides derived from mutated proteins to CD8+ T cells, thereby playing a crucial role in the adaptive immune response. By creating a tetramer that combines HLA-A*11:01 with β2-microglobulin (B2M) and the specific KRAS G12D peptide, researchers can effectively identify and characterize T cell populations that respond to this mutation. This approach aids in deciphering the immune landscape surrounding KRAS-driven tumors, enhancing our understanding of how the immune system interacts with cancer cells. Ultimately, the development of this tetramer may contribute to the advancement of immunotherapeutic strategies, including personalized cancer vaccines and adoptive T cell therapies, thus providing insights into more effective treatments for patients with KRAS-mutant cancers.
